A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Idiopathic Inflammatory Myopathy (IIM)

Interventions

COMBINATION_PRODUCT

CLBR001 + SWI019

Investigational switchable CAR-T cell therapy for autoimmune disorders

All Listed Sponsors

lead

Calibr, a division of Scripps Research

OTHER

NCT06913608 - A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases | Biotech Hunter | Biotech Hunter